Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival

doi:10.4251/wjgo.v8.i3.248

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10673)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

693

WORD

400

HTML

3864

Figures (1-1)

272

Tables (1-4)

265

Sum=5494

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

490

Download

1461

Sum=1951

Publishing Process of This Article

Item

Count

Browse

1170

Download

2058

Sum=3228

Mar 15, 2016 (publication date) through Feb 7, 2025

Times Cited of This Article

Times Cited (20)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Oncol. Mar 15, 2016; 8(3): 248-257
Published online Mar 15, 2016. doi: 10.4251/wjgo.v8.i3.248

Table 2 Completed adjuvant phase III trials

Ref.	Treatment group	Median OS (mo)	3-yr-survival	5-yr-survival
CONKO-001[38,39]	Gem	22.8	37%	21%
CONKO-001[38,39]	Observation	20.2	20%	9%
ESPAC-3[40]	Gem	23.6
ESPAC-3[40]	5-FU/folinsäure	23.0
JASPAC-01[43]	S1		2 yr 70%
JASPAC-01[43]	Gem		2 yr 53%
RTOG 97-04	RCT + Gem	20.5	31%	24%
(pancreatic head)[57]	RCT + 5-FU/FS	16.9	22%	11%
CONKO-005[45]	Gem + Erlotinib	24.6	36%	28%
CONKO-005[45]	Gem	26.5	33%	19%

5-FU: 5-flourouracil; OS: Overall survival.

Citation: Sinn M, Bahra M, Denecke T, Travis S, Pelzer U, Riess H. Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival. World J Gastrointest Oncol 2016; 8(3): 248-257
URL: https://www.wjgnet.com/1948-5204/full/v8/i3/248.htm
DOI: https://dx.doi.org/10.4251/wjgo.v8.i3.248